Abstract 2300P
Background
Immunotherapy is one of the mainstays of lung cancer treatment. However, the results presented in pivotal trials do not always reflect those in real life, as patients (pts) are more selected for prognostic factors. Cancer is associated with advanced age, and aging is the main risk factor for developing CHIP, a clonal expansion of mutations affecting genes involved in hematologic malignancies in pts without a hematological disease per se.
Methods
We performed a Next-Generation Sequencing (NGS) panel of 74-genes dedicated to hematological alterations on DNA extracted from whole blood collected before first administration of an ICB for advanced NSCLC, within the PREMIS trial (NCT03984318). CHIP prevalence was assessed according to a variant allele frequency (VAF) threshold of 2%. The main objective is to evaluate CHIP prevalence in a prospective cohort of pts treated with ICB for NSCLC correlating CHIP with clinical outcomes.
Results
We included 104 pts; 68 pts (65%) male, median age of 68 years [range 31-87], and adenocarcinoma represented 68% of cases. ICB setting was 1°L 41%; 2°L 47%; ≥ 3°L 11%, and the most used ICB was Pembrolizumab in 63% of pts. Finally, 98 pts were retained for the analysis. At least 1 CHIP mutation was found in 47 pts (48%).The most frequent mutations were found in DNMT3A (69%), PPM1D (17%), TET2, ASXL1 and CHEK2 genes (7% respectively). Median PFS was 2.6 months (m) for CHIP vs 9.3 m no-CHIP 12 m (p=0.02) and median OS was 9.3 m CHIP vs 15 m no-CHIP (p=0.11), associated to lower percentage of PD-L1 and a higher number of metastatic sites in the multivariate analysis. No pts developed hematological disease during the follow up.
Conclusions
CHIP is commonly found in pts with NSCLC, with a prevalence in our cohort of 48% with statistically significant worse PFS in the CHIP-positive population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Marabelle: Financial Interests, Personal, Advisory Board: Gritstone, Innate Pharma, Neogene, Deka Biosciences, Hotspot Therapeutics, Johnson & Johnson, Depth Charge, Bioline Rx, Clover Biopharmaceuticals, Grey Wolf Therapeutics, Lytix Biopharma, RedX Pharma, HiFiBiO Therapeutics, ImCheck Therapeutics, Shattuck Labs, Marengo Therapeutics, PegaOne; Financial Interests, Personal, Other, Associate Editor: European Journal of Cancer; Financial Interests, Personal, Stocks/Shares: HiFiBiO Therapeutics, Deka Biosciences, HotSpot Therapeutics, Shattuck Labs; Financial Interests, Institutional, Research Grant: BMS, AstraZeneca, Sanofi; Financial Interests, Institutional, Coordinating PI: IMCheck, SOTIO, Roche/Genentech, MSD, BMS, OSE Immunotherapeutics, Eisai, Pierre Fabre, Adlai Nortye, Molecular Partners; Financial Interests, Steering Committee Member: Roche; Financial Interests, Institutional, Funding: Transgene; Non-Financial Interests, Other, Associate Editor: IOTECH Journal; Non-Financial Interests, Institutional, Product Samples: BMS, Idera, MSD, Transgene; Non-Financial Interests, Leadership Role: Société Française d'Immunothérapie des Cancers; Non-Financial Interests, Member: Society for Immunotherapy of Cancer, American Association for Cancer Research, American Society for Clinical Oncology; Other, Consultant: Third Rock Ventures, Guidepoint; Other, Advisor: Medicxi. B. Besse: Financial Interests, Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals; Financial Interests, Institutional, Research Grant: Genzyme Corporation, Chugai Pharmaceutical, Eisai, Inivata, Ipsen, Turning Point Therapeutics. J. Baptiste Micol: Financial Interests, Advisory Board: AbbVie, Jazz Pharmaceuticals; Financial Interests, Personal, Other: AbbVie, Jazz Pharma, Astellas. S. Ponce Aix: Financial Interests, Advisory Board: Roche, MSD, AstraZeneca, Bristol Myers Squibb, PharmaMar, Boehringer Ingelheim, BMS. Expert testimony: Roche, MSD, AstraZeneca, Bristol Myers Squibb, PharmaMar, Boehringer Ingelheim, BMS. Travel, accommodations, expenses: MSD, Roche, BMS, AstraZeneca, Ph; Financial Interests, Speaker, Consultant, Advisor: Bristol Myers Squibb. C. Marzac: Financial Interests, Advisory Board: Astellas. C. Massard: Other, Consultant/Advisory fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion Principal/sub-Investigator of Clinical Trials for AbbVie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo Pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boehringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 Biomedicine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, MedImmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, PharmaMar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, Xencor: Company. C. Baldini: Other, Institutional, Principal Investigator: AbbVie, Adaptimmune, Adlai Nortye USA Inc., Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca Ab, Aveo, Basilea Pharmaceutica International Ltd., Bayer Healthcare Ag, Bbb Technologies Bv, Beige; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Financial Interests, Funding: BMS Fundation; Financial Interests, Speaker, Consultant, Advisor: Bicycle Therapeutics, Rising Tide Fundation, ITEOS. All other authors have declared no conflicts of interest.
Resources from the same session
2315P - Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 08
2316P - Integrating comprehensive cancer genome profiling into clinical practice in an Italian referral center: Results of the first year of the fpg500 programme
Presenter: Camilla Nero
Session: Poster session 08
2317P - Mutational landscape and therapeutic implications in squamous cell carcinomas
Presenter: Laila Belcaid
Session: Poster session 08
2318P - Value of broad molecular profiling for cancer diagnosis
Presenter: Lars Volker Anton Werstein
Session: Poster session 08
2319P - CADSP: A web tool for comprehensive drug sensitivity analysis in pan-cancer
Presenter: Kexin Li
Session: Poster session 08
2320P - Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma
Presenter: Peter Horak
Session: Poster session 08
2321TiP - TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial
Presenter: Christine Federspiel Secher
Session: Poster session 08
2322TiP - SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvage-therapy matching in patients with advanced and refractory carcinoma
Presenter: Jakob Riedl
Session: Poster session 08